Juliane Haedicke

Juliane Haedicke

Auto-generated profile, based on publicly available information

Juliane Haedicke

Division of Experimental Virology, Institute of Medical Virology, University Hospital Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JHJuliane Haedicke
Juliane Haedicke
TIThomas Iftner
Thomas Iftner
Human papillomaviruses (HPV) are small oncogenic DNA viruses of which more than 200 types have been identified to date. A small subset of these is etiologically linked to the development of anogenital malignancies such as cervical cancer. In addition, recent studies established a causative relationship between these high-risk HPV types and tonsillar and oropharyngeal cancer. Clinical management of cervical cancer and head and neck squamous cell carcinomas (HNSCCs) is largely standardized and involves surgical removal of the tumor tissue as well as adjuvant chemoradiation therapy. Notably, the response to therapeutic intervention of HPV-positive HNSCCs has been found to be better as compared to HPV-negative tumors. Although the existing HPV vaccine is solely licensed for the prevention of cervical cancer, it might also have prophylactic potential for the development of high-risk HPV-associated HNSCCs. Another group of viruses, which belongs to the beta-HPV subgroup, has been implicated in nonmelanoma skin cancer, however, the etiology remains to be established. Treatment of HPV-induced nonmelanoma skin cancer is based on local excision. However, topically applied immune-modulating substances represent non-surgical alternatives for the management of smaller cutaneous tumors. In this review we present the current knowledge of the role of HPV in cancer development and discuss clinical management options as well as targets for the development of future intervention therapies.

1 August 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
TIThomas Iftner
Thomas Iftner
SBSven Becker
Sven Becker
KNKlaus-Joachim Neis
Klaus-Joachim Neis
Alejandra CastanonAlejandra Castanon
Alejandra Castanon
AIAngelika Iftner
Angelika Iftner
PSPeter Sasieni
Peter Sasieni
Testing for E6/E7 mRNA in cells infected with high-risk (HR) human papillomavirus (HPV) might improve the specificity of HPV testing for the identification of cervical precancerous lesions. Here we compared the RNA-based Aptima HPV (AHPV) assay (Hologic) and the DNA-based Hybrid Capture 2 (HC2) HPV test (Qiagen) to liquid-based cytology (LBC) for women undergoing routine cervical screening. A total of 10,040 women, 30 to 60 years of age, were invited to participate in the study, 9,451 of whom were included in the analysis. Specimens were tested centrally by LBC, the AHPV test, and the HC2 test, and women who tested positive on any test were referred for colposcopy. Genotyping was performed on all HR-HPV-positive samples. Test characteristics were calculated based on histological review. As a result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), including 43 women with CIN3+. Sensitivity differences between the AHPV test and the HC2 test in detecting CIN2+ ( P = 0.180) or CIN3+ ( P = 0.0625) lesions were statistically nonsignificant. Of three CIN3 cases that were missed with the AHPV test, two cases presented lesion-free cones and one had a non-HR HPV67 infection. The specificity (<CIN2) and positive predictive value (CIN2+) of the AHPV test were significantly higher (both P < 0.001) than those of the HC2 test. The overall agreement between the tests was substantial (κ = 0.77). Finally, we present results for several possible triage strategies, based on the primary screening test being either the AHPV test or the HC2 test. In summary, the AHPV assay is both specific and sensitive for the detection of high-grade precancerous lesions and may be used in primary cervical cancer screening for women ≥30 years of age.

1 March 2016 in Journal of Clinical Virology
Verified
Journal Article
Open access
JHJuliane Haedicke
Juliane Haedicke
TIThomas Iftner
Thomas Iftner
This comprehensive review compiles published data from 62 original articles comparing different HPV tests and one meta-analysis on the clinical performance of the Aptima HR HPV (AHPV) assay in either screening or referral populations as well as for the purpose of test of cure. A number of publications with technical issues were also considered. Besides a brief introduction in the development of E6/E7 mRNA testing, the review summarizes data on analytical sensitivies and specificities, as well as on clinical sensitivity, specificity, NPV and PPV with histological endpoints CIN2+ and CIN3+, where available. Although most studies were of cross-sectional design, five studies with a longitudinal prospective design or component were identified. In addition to the study design, sample size, age and CIN2/3+ prevalence of the respective cohort are listed. This allows direct comparison of the published data in the respective groups. One major outcome of this review is the remarkably stable similar sensitivities of AHPV and HC2 independent from study design for detection of CIN2/3+ combined with a higher specificity of the AHPV. The second outcome was the longitudinal predictive value derived from registry linkage and other prospective studies that would support the applicability of the AHPV test in primary screening with at least a three year screening interval.

1 March 2017 in Virus Research
Verified
Journal Article
Closed access
TIThomas Iftner
Thomas Iftner
JHJuliane Haedicke-Jarboui
Juliane Haedicke-Jarboui
SWShwu-Yuan Wu
Shwu-Yuan Wu
CCCheng-Ming Chiang
Cheng-Ming Chiang

1 May 2008 in Journal of Virology
Verified
Journal Article
Closed access
JHJuliane Haedicke
Juliane Haedicke
KSKenia de Los Santos
Kenia de Los Santos
SGStephen P. Goff
Stephen P. Goff
MNMojgan H. Naghavi
Mojgan H. Naghavi
We recently identified the cytoskeletal regulatory protein moesin as a novel gene that inhibits retroviral replication prior to reverse transcription by downregulation of stable microtubule formation. Here, we provide evidence that overexpression of ezrin, another closely related ezrin-radixin-moesin (ERM) family member, also blocks replication of both murine leukemia viruses and human immunodeficiency virus type 1 (HIV-1) in Rat2 fibroblasts before reverse transcription, while knockdown of endogenous ezrin increases the susceptibility of human cells to HIV-1 infection. Together, these results suggest that ERM proteins may be important determinants of retrovirus susceptibility through negative regulation of stable microtubule networks.

13 November 2018 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
OROlga Rataj
Olga Rataj
JHJuliane Haedicke‐Jarboui
Juliane Haedicke‐Jarboui
FSFrank Stubenrauch
Frank Stubenrauch
TIThomas Iftner
Thomas Iftner
Although a vast amount of research underlines the roles of the HR HPV E6 and E7 oncogenes in HPV‐induced carcinogenesis of cervical cancer, it remains unclear whether these oncogenes are also involved in the resistance of the cancer against chemotherapy.We examined the role of the HPV16 E6 oncogene in cisplatin resistance by analyzing its expression in newly established cisplatin‐sensitive versus ‐resistant cervical cancer cell lines (CC7, CC10). Resistant variants were obtained by interval exposure treatment with 1–2 μM cisplatin for 8–9 months. Our results demonstrate that the expression level of HPV16 E6 directly correlates with the extent of cisplatin resistance in novel as well as established (SiHa) drug resistant cervical cancer cell lines. Overexpression of HPV16 E6 in cisplatin‐naïve cells rendered these cells more resistant to cisplatin. Reducing E6 expression by JQ1 treatment reversed the drug resistant phenotype and strongly enhanced chemoresponse only in HPV‐positive cisplatin‐resistant variants and not in HPV‐negative C33A cervical cancer cells. The level of E6 directly correlated with the extent of cisplatin sensitivity and was shown to be increased in newly established drug‐resistant cell line variants, while reducing E6 expression using Brd4‐inhibitors enhanced chemoresponse when co‐delivered with cisplatin. Inhibition of Brd4 could represent a new therapeutic option by increasing treatment response in cervical cancer cells and might allow lower cisplatin dosages, thus reducing negative side effects.